Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

A Lancet study shows promising results for an annual HIV prevention injection, lenacapavir. In Stage 1 trials, 40 HIV-negative participants had no significant side effects ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

The Trump administration has cut around 100 employees, or roughly 10%, of the federal agency that oversees mental and ...

Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...